Premium
Effects of high‐dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease
Author(s) -
Alvarez Jessica A,
Zughaier Susu M,
Law Jennie,
Hao Li,
Wasse Haimanot,
Ziegler Thomas R,
Tangpricha Vin
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.46.3
Subject(s) - cholecalciferol , medicine , vitamin d and neurology , cathelicidin , inflammation , kidney disease , immune system , vitamin d deficiency , monocyte , placebo , endocrinology , immunity , immunology , gastroenterology , innate immune system , pathology , alternative medicine
Objective Few have investigated the anti‐inflammatory and immune‐regulating effects of vitamin D in patients with early chronic kidney disease (CKD). We aimed to determine if high‐dose cholecalciferol supplementation for 1 yr in subjects with early CKD reduced serum monocyte chemoattractant protein‐1 (MCP‐1) and other markers of inflammation and immunity. Methods In a double‐blind, randomized, placebo‐controlled trial, 46 subjects with stage 2–3 CKD were given oral cholecalciferol (50 000 IU weekly for 12 wks then 50 000 IU every other wk) or placebo for 1 yr. Serum MCP‐1, tumor necrosis factor‐α, interleukin‐6, and cathelicidin were measured. An in vitro experiment was performed to investigate the effect of 1,25‐dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) treatment on MCP‐1 secretion in THP‐1 monocytes activated with lipopolysaccharide and Pseudomonas aeruginosa.Results By 12 wks, serum MCP‐1 decreased in the cholecalciferol group (Figure). Other markers of inflammation and immunity did not change. Percent change in 25‐hydroxyvitamin D by 12 wks was associated with % change in MCP‐1 (r = −0.43, P = 0.005). In vitro , activated monocytes treated with1,25(OH) 2 D 3 had less MCP‐1 secretion compared to control cells ( P < 0.05). Conclusions These clinical and in vitro studies support a role for vitamin D in the regulation of immune‐mediated processes in patients with early CKD, specifically in the reduction of MCP‐1. Grant Funding Source : NIH, Atlanta Research and Education Foundation